Major Pharmaceuticals Recalls Enalapril Maleate Tablets Due to Impurities
Major Pharmaceuticals is recalling 5,933 cartons of Enalapril Maleate Tablets, 5 mg, due to out-of-specification degradation products.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Major Pharmaceuticals is recalling 5,933 cartons of Enalapril Maleate Tablets, USP, 5 mg, 100 Tablets (10 x 10) Unit Dose per carton. The product is distributed nationwide in the USA and Puerto Rico. The recall is a sub-recall initiated because the manufacturing firm, Wockhardt, recalled the repackaged product due to out-of-specification results for the Enalapril DiKetopiperazine degradation product.
The affected lots include T-01082 (Exp 08/18), DR10445A (Exp 09/18), DR10443A (Exp 12/18), DR10445B (Exp 03/19), DR10725A (Exp 07/19), and DS10024A, DS10040A (Exp 10/19). The product is manufactured by Wockhardt Limited and distributed by Wockhardt USA LLC and Major Pharmaceuticals.
The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences. Patients and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed above and stop using the product if it matches the recall criteria.
The recalled product
- Product
- Enalapril Maleate Tablets, USP, 5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufactured by: Wockhardt Limited, H-14/2, M.I.D.C. Area, Waluj, Aurangabad, Maharashtra, India; Distributed by: Wockhardt USA LLC., 20 Waterview Blvd., Parsippany, NJ 07054; Distributed
- Manufacturer
- MAJOR PHARMACEUTICALS
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 5,933
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- Lot #: T-01082
- Exp 08/18
- DR10445A
- Exp 09/18
- DR10443A
- Exp 12/18
- DR10445B
- Exp 03/19
- DR10725A
- Exp 07/19
- DS10024A
- DS10040A
- Exp 10/19.
Distribution
Part of a larger recall action
This product is one of 2 recalled by MAJOR PHARMACEUTICALS under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · MAJOR PHARMACEUTICALS
See all →- HighLevothyroxine Sodium Tablets Recalled for Subpotency by Major Pharmaceuticals
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency Nationwide
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-29
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08